NAFLD/NASH: Updates & Treatment Options
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Nonalcoholic fatty liver disease and steatohepatitis are well-recognized clinical concerns. What are we learning from the latest research? What is the diagnostic value of liver biopsy? Dr. Naga Chalasani, professor of medicine in the division of gastroenterology and hepatology at Indiana University School of Medicine, also examines the manifestation and risk profile of each disease with host Dr. Jay Goldstein. How do statins factor into current treatment patterns?
Overview
Nonalcoholic fatty liver disease and steatohepatitis are well-recognized clinical concerns. What are we learning from the latest research? What is the diagnostic value of liver biopsy? Dr. Naga Chalasani, professor of medicine in the division of gastroenterology and hepatology at Indiana University School of Medicine, also examines the manifestation and risk profile of each disease with host Dr. Jay Goldstein. How do statins factor into current treatment patterns?
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
Level Up Your Skills: Tailoring Management of HF
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?